Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 x 10e9.L and transfusion independent plt count >20 x 10e9.L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 x 10e9.L at 30 days was 87% and transfusion independent plt count >20 x 10e9.L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.
|Titolo:||Nonmyeloablative conditioning, unmanipulated haploidentical stem cell transplantation and post-infusion cyclophosphamide for advanced lymphomas|
|Data di pubblicazione:||2014|
|Appare nelle tipologie:||1.1 Articolo in rivista|